Citigroup, whose investment bank is run by ex-JPMorgan banker Vis Raghavan, has taken the biggest hit to its share of deals ...
Major stock indexes finished mixed Friday, with the Dow Jones Industrial Average declining for a second straight session but ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
US Stock Market Highlights: Nasdaq snaps three-day slide as tech stocks rebound after sharp sell-off
US stocks declined on Friday (November 14), extending losses after Wall Street recorded its worst session in over a month.
Key Takeaways Merck agreed to pay $9.2 billion to purchase Cidara Therapeutics, looking to cash in on the firm's experimental flu treatment.The $221.50 per share offer is more than twice Cidara's ...
Merck & Co. agreed to acquire Cidara Therapeutics Inc., a biotech company developing a flu treatment, as part of its ongoing ...
Cidara Therapeutics, Inc. surges to $217 on a bid by Merck & Co., Inc. valuing shares at $221.50. Learn more about CDTX stock ...
Merck announced the $9.2 billion deal with Cidara on Friday, sending Cidara's stock (CDTX) soaring 106% in recent morning trading, enough to make it the biggest gainer on the major U.S. exchanges. The ...
“We don’t suffer from FOMO [fear of missing out],” says the portfolio manager and senior wealth adviser with Propellus Wealth ...
Merck will acquire Cidara Therapeutics for $9.2B to expand its respiratory portfolio, driven by demand for CD388 as ...
Cidara Therapeutics (CDTX) stock surge 100% as Merck acquires biotech for $9.2B at $221.50 per share, triple its previous ...
Merck & Co. Inc. (NYSE: MRK) on Friday agreed to acquire Cidara Therapeutics, Inc. (NASDAQ: CDTX) for $221.50 per share in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback